⏳ Fetching live dividend data...
Home › Calculator › MGTA Dividend Calculator 2026
Magenta Therapeutics, Inc. · NASDAQ
Price: $0.70 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in MGTA → $7319.75M in 10 years · $451,903,304.18/month
Magenta Therapeutics, Inc. is a biotechnology firm in the clinical development stage, dedicated to advancing therapies that leverage the transformative potential of stem cell transplantation for individuals afflicted with blood cancers, genetic illnesses, and autoimmune conditions. Among its key pipeline candidates is MGTA-117, an anti-CD117 antibody. This compound specifically targets hematopoietic stem cells (HSCs) and the genetically altered stem cells implicated in acute myeloid leukemia and myelodysplastic syndromes, and is currently progressing through Phase I/II clinical trials. Additionally, the company is developing a CD45-antibody drug conjugate, designed to target both HSCs and immune cells. This asset is in investigational new drug (IND) enabling studies, exploring its potential as a monotherapy for autoimmune diseases and in hematology-oncology transplant settings. Another therapeutic, MGTA-145, is undergoing Phase II clinical evaluation for its application in both autologous and allogeneic transplant procedures. Beyond these, Magenta boasts a cell therapy initiative featuring E478, a small molecule aryl hydrocarbon receptor antagonist, which is being explored for stem cell-based gene therapy and genome editing. The company actively engages in strategic alliances, including a research and clinical collaboration with AVROBIO, Inc. focused on treating lysosomal storage disorders. Furthermore, it partners with Beam Therapeutics, Inc. to investigate the utility of MGTA-117 as a conditioning regimen for patients with sickle cell disease and beta-thalassemia. Originally incorporated in 2015 as HSCTCo Therapeutics, Inc., the company adopted its current name, Magenta Therapeutics, Inc., in February 2016. Its corporate headquarters are situated in Cambridge, Massachusetts.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open MGTA position with:
Real after-tax yield depends on where you live and how you hold MGTA.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 285.88% | 283.08% | $28,588 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 243.00% | 240.20% | $24,300 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 228.70% | 225.90% | $22,870 / yr |
| 🇬🇧 UK ISA | 0% | 285.88% | 283.08% | $28,588 / yr |
| 🇬🇧 UK Taxable | 8.75% | 260.87% | 258.07% | $26,087 / yr |
| 🇨🇦 TFSA | 0% | 285.88% | 283.08% | $28,588 / yr |
| 🇨🇦 CA Taxable | 25% | 214.41% | 211.61% | $21,441 / yr |
| 🇦🇺 Super (pension) | 15% | 243.00% | 240.20% | $24,300 / yr |
| 🇦🇺 AU Taxable | 30% | 200.12% | 197.32% | $20,012 / yr |
| 🇩🇪 DE Taxable | 26.375% | 210.48% | 207.68% | $21,048 / yr |
| 🇫🇷 FR Taxable | 30% | 200.12% | 197.32% | $20,012 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
MGTA pays quarterly — 4 times per year. Next ex-div: TBD.
How MGTA compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for MGTA sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| Buy | 2023-09-29 | 24,670 | $13.63 | $336.3K | ||
| Buy | 2023-09-26 | 30,000 | $13.15 | $394.5K | ||
| Buy | 2023-09-22 | 2,000 | $13.20 | $26.4K | ||
| Buy | 2023-09-21 | 2,000 | $13.20 | $26.4K | ||
| Buy | 2023-09-19 | 30,000 | $13.20 | $396.0K | ||
| A-Award | 2023-09-11 | 6,500 | $11.20 | $72.8K | ||
| A-Award | 2023-09-11 | 6,500 | $11.20 | $72.8K | ||
| Buy | 2023-09-13 | 9,367 | $11.76 | $110.2K | ||
| Buy | 2023-09-12 | 14,887 | $10.85 | $161.5K | ||
| A-Award | 2023-09-11 | 6,500 | $11.20 | $72.8K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the MGTA dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Magenta Therapeutics, Inc. (MGTA) is currently trading at $0.70, 95% below its 52-week high. The current dividend yield is 285.88% based on an annual payout of $2.00 per share.
Magenta Therapeutics, Inc. (MGTA) is a healthcare stock currently trading at $0.70 with a dividend yield of 285.88%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
Auto-generated from live market data. For educational purposes only — not financial advice.
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →